ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Commends Final LCDs
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination...
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2024.
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases...
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis (ORGO) Q2 2024 Earnings Call Transcript
ORGO earnings call for the period ending June 30, 2024.
ORGO Stock Earnings: Organogenesis Hldgs Beats Revenue for Q2 2024
ORGO stock results show that Organogenesis Hldgs beat on revenue for the second quarter of 2024.
ORGO Stock Earnings: Organogenesis Hldgs Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organogenesis Hldgs (NASDAQ:ORGO) just reported results for the second quarter ...
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Shares ReNu® Program Update
On track to submit ReNu BLA by the end of 2025Enrollment in second Phase 3 complete; significantly ahead of expectationsSubgroup analysis demonstrated most...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN
ORGO Stock Earnings: Organogenesis Hldgs Beats EPS, Beats Revenue for Q1 2024
ORGO stock results show that Organogenesis Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
ORGO Stock Earnings: Organogenesis Hldgs Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organogenesis Hldgs (NASDAQ:ORGO) just reported results for the first quarter o...
Organogenesis (ORGO) Q1 2024 Earnings Call Transcript
ORGO earnings call for the period ending March 31, 2024.
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Commit To Purchase Organogenesis Holdings At $2.50, Earn 33.2% Annualized Using Options
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.
Why Organogenesis Holding Stock Plummeted by 18% Today
A double miss put the wound care specialist's shares on the sick list.
Organogenesis (ORGO) Q4 2023 Earnings Call Transcript
ORGO earnings call for the period ending December 31, 2023.
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...
